BlackRock Health Sciences Term Trust (NYSE:BMEZ - Get Free Report) major shareholder Saba Capital Management, L.P. bought 46,421 shares of the company's stock in a transaction that occurred on Monday, April 1st. The stock was purchased at an average cost of 16.33 per share, for a total transaction of 758,054.93. Following the transaction, the insider now owns 20,538,431 shares in the company, valued at approximately 335,392,578.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Thursday, March 28th, Saba Capital Management, L.P. bought 16,297 shares of BlackRock Health Sciences Term Trust stock. The stock was purchased at an average cost of 16.33 per share, for a total transaction of 266,130.01.
- On Tuesday, March 26th, Saba Capital Management, L.P. purchased 129,372 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 16.32 per share, for a total transaction of 2,111,351.04.
- On Thursday, February 29th, Saba Capital Management, L.P. purchased 46,958 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 16.30 per share, for a total transaction of 765,415.40.
- On Monday, February 26th, Saba Capital Management, L.P. purchased 113,930 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 16.34 per share, for a total transaction of 1,861,616.20.
- On Thursday, February 22nd, Saba Capital Management, L.P. purchased 154,932 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 16.13 per share, for a total transaction of 2,499,053.16.
- On Tuesday, February 20th, Saba Capital Management, L.P. purchased 193,297 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 15.92 per share, for a total transaction of 3,077,288.24.
- On Thursday, February 15th, Saba Capital Management, L.P. purchased 41,462 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 15.82 per share, for a total transaction of 655,928.84.
- On Monday, February 12th, Saba Capital Management, L.P. purchased 83,360 shares of BlackRock Health Sciences Term Trust stock. The shares were bought at an average cost of 16.08 per share, for a total transaction of 1,340,428.80.
- On Friday, February 9th, Saba Capital Management, L.P. bought 122,094 shares of BlackRock Health Sciences Term Trust stock. The shares were acquired at an average price of 15.97 per share, with a total value of 1,949,841.18.
- On Wednesday, February 7th, Saba Capital Management, L.P. bought 100,354 shares of BlackRock Health Sciences Term Trust stock. The shares were acquired at an average price of 15.81 per share, with a total value of 1,586,596.74.
BlackRock Health Sciences Term Trust Trading Down 0.6 %
Urgent dollar warning
From Stansberry Research | Ad
Your 2024 Election Money Blueprint
Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.
Find out for free here.
Shares of NYSE BMEZ opened at 15.81 on Thursday. BlackRock Health Sciences Term Trust has a 12 month low of 12.93 and a 12 month high of 16.95. The stock has a 50 day moving average of 16.05 and a 200-day moving average of 14.85.
BlackRock Health Sciences Term Trust Announces Dividend
The firm also recently announced a monthly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Monday, April 15th will be paid a dividend of $0.09 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $1.08 annualized dividend and a dividend yield of 6.83%.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. boosted its stake in shares of BlackRock Health Sciences Term Trust by 17.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 30,559 shares of the company's stock worth $448,000 after acquiring an additional 4,604 shares during the period. Virtu Financial LLC boosted its stake in BlackRock Health Sciences Term Trust by 71.2% in the 4th quarter. Virtu Financial LLC now owns 19,857 shares of the company's stock valued at $291,000 after purchasing an additional 8,256 shares during the period. Citadel Advisors LLC bought a new stake in BlackRock Health Sciences Term Trust in the 4th quarter valued at $431,000. Royal Bank of Canada boosted its stake in BlackRock Health Sciences Term Trust by 16.9% in the 4th quarter. Royal Bank of Canada now owns 358,116 shares of the company's stock valued at $5,247,000 after purchasing an additional 51,893 shares during the period. Finally, Pathstone Holdings LLC bought a new stake in BlackRock Health Sciences Term Trust in the 4th quarter valued at $222,000.
About BlackRock Health Sciences Term Trust
(
Get Free Report)
BlackRock Health Sciences Trust II’s (BMEZ) (the 'Trust') investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
